Comparison
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470 vs Abdominal Obesity Metabolic Syndrome 4 C5231430
Clinical comparison between 46 XY Disorder OF Sex Development Due TO Isolated 17 20 Lyase Deficiency and Abdominal Obesity Metabolic Syndrome 4 for differential diagnosis and treatment planning.
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
A rare condition involving deficiency of the 17,20-lyase enzyme needed for androgen synthesis. Affects 46,XY individuals and causes undervirilization. Managed with hormone therapy.
Abdominal Obesity Metabolic Syndrome 4 C5231430
Another genetic subtype of metabolic syndrome with distinct inherited features. Like other forms, it involves obesity and metabolic disturbances. Management includes diet, exercise, and monitoring for related conditions.
6 comparison axes
Onset
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
0-0
Abdominal Obesity Metabolic Syndrome 4 C5231430
20-50
Onset patterns differ
Severity
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
severe
Abdominal Obesity Metabolic Syndrome 4 C5231430
moderate
Different severity levels
Chronic
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
Chronic
Abdominal Obesity Metabolic Syndrome 4 C5231430
Chronic
Differing course
Communicable
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
No
Abdominal Obesity Metabolic Syndrome 4 C5231430
No
Different transmission
Body System
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
reproductive
Abdominal Obesity Metabolic Syndrome 4 C5231430
metabolic
Same/different system
Category
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
endocrine
Abdominal Obesity Metabolic Syndrome 4 C5231430
genetic
Different category
Bottom line
46-xy-disorder-of-sex-development-due-to-isolated-17-20-lyase-deficiency-C5681470 and abdominal-obesity-metabolic-syndrome-4-C5231430 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470 | Abdominal Obesity Metabolic Syndrome 4 C5231430 | Discriminating power |
|---|---|---|---|
| Genital development | Undervirilization or atypical genital development may be present from birth. | No primary genital developmental disorder is described. | High |
| Body-fat pattern | Abdominal obesity is not a defining feature. | Abdominal obesity is a central reported feature. | High |
| Age at recognition | Typically recognized in infancy or childhood, sometimes later. | Usually considered in adulthood, often ages 20–50. | Moderate |
When to favor each condition
Choose 46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470 when
46,XY infant with undervirilization
The presentation aligns with impaired androgen synthesis rather than metabolic syndrome.
High
Suspected isolated 17,20-lyase deficiency
Specialist endocrine and genetic evaluation can assess this rare diagnosis.
Moderate
Need for sex-hormone assessment
Hormone therapy may be considered, but regimen must be individualized.
Moderate
Choose Abdominal Obesity Metabolic Syndrome 4 C5231430 when
Adult with abdominal obesity and metabolic abnormalities
This pattern fits the described metabolic-syndrome subtype better than a DSD.
High
Family history suggesting inherited metabolic syndrome
A genetic subtype may be considered, although subtype 4 is not established by symptoms alone.
Low
Cardiometabolic risk monitoring
Diet, activity, and surveillance for related conditions are central to management.
Moderate
How key tests differ
| Test | 46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470 | Abdominal Obesity Metabolic Syndrome 4 C5231430 | Interpretation |
|---|---|---|---|
| Karyotype | 46,XY is part of the condition definition. | No characteristic karyotype is established. | Karyotype supports classification of the DSD but does not diagnose the metabolic condition. |
| Steroid hormone profile | Pattern may suggest impaired androgen synthesis; exact cutoffs are not supplied. | No specific steroid-synthesis defect is described. | Abnormal results require specialist interpretation and are not themselves a definitive diagnosis. |
| Metabolic panel and anthropometry | No defining glucose, lipid, or waist-circumference abnormality is established. | Obesity and metabolic disturbances are expected, without supplied numeric thresholds. | Results support metabolic risk assessment but do not prove the genetic subtype. |
Prognosis comparison
46 Xy Disorder Of Sex Development Due To Isolated 17 20 Lyase Deficiency C5681470
- Outcome
- Chronic condition with variable developmental and hormonal effects; exact outcomes are not established.
- Factors
- Timing of recognition, degree of undervirilization, and response to individualized hormone care.
Abdominal Obesity Metabolic Syndrome 4 C5231430
- Outcome
- Chronic metabolic condition whose course depends on risk-factor control; mortality data are not supplied.
- Factors
- Weight pattern, metabolic abnormalities, inherited features, and adherence to lifestyle monitoring.
Time frame: Lifelong follow-up may be appropriate; no reliable shared timeline is established.
Diagnosis confirmation, associated conditions, treatment response, and access to specialist care.
Complications comparison
| Complication | Presentation |
|---|---|
| Reproductive or sexual development concerns | Undervirilization and related developmental concerns may occur. Not a described primary complication. Impact varies; fertility and puberty outcomes are not established here. |
| Cardiometabolic disease | Not an established defining complication. Related metabolic conditions may develop and warrant monitoring. Specific rates and outcomes are not provided. |
| Treatment-related burden | Long-term hormone therapy and specialist follow-up may be needed. Lifestyle treatment and ongoing risk monitoring are emphasized. Neither condition has a universally fixed treatment course in these data. |
Patient education highlights
- HighDifferent conditions
One affects sex-hormone synthesis and development; the other concerns obesity and metabolism. They are not interchangeable diagnoses.
- HighSpecialist confirmation
Abnormal tests or physical findings need clinician interpretation and should not be self-diagnosed.
- MediumLong-term care
Both are described as chronic, but follow-up goals and treatments differ substantially.